VOLITIONRX LTD. overview

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis PR Newswire HENDERSON, Nev., Feb. 6, 2025 Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that...

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 PR Newswire HENDERSON, Nev., Feb. 5, 2025 HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET , featuring Volition company management Dr. Andrew Retter , Chief Medical Officer and Gael Forterre,...

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis PR Newswire HENDERSON, Nev., Jan. 30, 2025 HENDERSON, Nev. , Jan. 30, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and...

Volition Issues Business Review 2024 PR Newswire HENDERSON, Nev., Jan. 8, 2025 HENDERSON, Nev. , Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide. Sold over 110,000 Nu.Q®...

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants PR Newswire HENDERSON, Nev., Dec. 12, 2024 Volition to participate in the upcoming 14 th Annual LifeSci Partners Corporate Access Event on January 15 th , 2025 at the Beacon Grand Hotel in San Francisco . HENDERSON, Nev. , Dec. 12, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained LifeSci Advisors, LLC ("LSA") a...

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening PR Newswire HENDERSON, Nev., Dec. 10, 2024 HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX ) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q ® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT ( LDCT ) scan, in patients...

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering PR Newswire HENDERSON, Nev, Dec. 6, 2024 Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive...

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update PR Newswire HENDERSON, Nev., Nov. 14, 2024 Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition...